文献速递中医内科中药与中成药合理使用中医康复

四君子汤改善慢性疲劳综合征疲劳症状及肠道菌群变化的随机双盲安慰剂对照多中心临床试验

Sijunzi decoction, a classical Chinese herbal formula, improves fatigue symptoms with changes in gut microbiota in chronic fatigue syndrome: A randomized, double-blind, placebo-controlled, multi-center clinical trial.
PubMed 文献 · Phytomedicine · 2024-04-13

本研究为多中心、双盲、随机安慰剂对照试验,纳入105例完成研究的慢性疲劳综合征兼脾虚证患者,评估四君子汤疗效与安全性。结果显示,在良好服药依从性下,四君子汤可改善疲劳症状和整体健康状况,且可能与调节肠道菌群有关。

要点

  • 四君子汤可改善慢性疲劳综合征患者的疲劳症状和整体健康状况。
  • 疗效在符合方案集分析中显著,意向性分析差异未达统计学显著。
  • 有益效应可能与调节肠道菌群,特别是乳酸片球菌丰度变化有关。

核心结论

  • 四君子汤能改善慢性疲劳综合征患者的疲劳症状和整体健康状况,尤其在良好服药依从性下。
  • 潜在治疗效应可能与调节肠道菌群有关。
  • 研究期间未发现严重不良事件或实验室检查异常。

研究设计与样本

  • 多中心、双盲、随机安慰剂对照临床试验。
  • 127例确诊慢性疲劳综合征兼脾虚证患者随机1:1分配,105例完成研究。
  • 干预为四君子汤或安慰剂颗粒,疗程2个月。

主要发现

  • 意向性分析中,四君子汤组CFQ评分平均变化6.65(SD 6.11)分,安慰剂组5.31(SD 5.19)分,差值1.34(95%CI -0.65至3.33)。
  • 符合方案集分析中,两组CFQ评分变化差异显著(差值2.24,95%CI 0.10至4.39)。
  • 符合方案集分析中,四君子汤组整体健康状况改善显著优于安慰剂组(p=0.009)。
  • SF36-PF、脾虚证量表评分和CGI变化两组间无显著差异。
  • 粪便宏基因组测序及相关分析提示,四君子汤有益效应可能与乳酸片球菌丰度变化有关。

临床怎么用

  • 对于慢性疲劳综合征兼脾虚证患者,可考虑使用四君子汤改善疲劳症状和整体健康状况。
  • 临床应用需关注患者服药依从性,良好依从性下疗效更明显。
  • 四君子汤可能通过调节肠道菌群发挥作用,但需进一步研究验证。

局限性

  • 意向性分析中CFQ评分差异未达统计学显著,仅符合方案集分析显著。
  • 研究样本量有限,完成研究105例。
  • 干预周期较短,仅2个月。
  • 需要更大规模、更长干预周期的试验进一步支持四君子汤的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUD: Chronic fatigue syndrome (CFS) severely impact patients' quality of life and lacks well-acknowledged drug therapy. Sijunzi decoction (SJZD), a classical Chinese herbal formula, has been widely used for spleen deficiency syndrome like fatigue in China. However, there is a lack of evidence on the efficacy of SJZD in treating CFS. PURPOSE: To evaluate the efficacy and safety of SJZD for CFS. STUDY DESIGN: A multi-center, double-blinded, randomized controlled trial. METHODS: Participants with definite diagnoses of CFS and spleen deficiency syndrome were randomly assigned in 1:1 ratio to receive SJZD or placebo granules for 2 months. The primary outcome was the change of Chalder fatigue questionnaire (CFQ) scoring after treatment. Other outcomes included changes in short form-36 physical function (SF36-PF) score, spleen deficiency scale score, Euroqol Questionnaire-Visual Analogue Scale (ED-VAS) score, and clinical global impression (CGI) evaluating by corresponding questionnaires. Fecal metagenome sequencing was conducted to explore the potential mechanism of SJZD effect. RESULTS: From June 2020 to July 2021, 105 of 127 participants completed the study at four hospitals in China. After a 2-month treatment, intention-to-treat (ITT) analysis found participants who received SJZD had larger reduction than placebo control (mean change 6.65 [standard deviation (SD) 6.11] points vs. 5.31 [SD 5.19] points; difference 1.34, 95 % confidence interval [CI] -0.65 to 3.33). Per-protocol (PP) analysis reported confirmative results with a significant difference between SJZD and placebo groups (2.24, 95 % CI 0.10 to 4.39). SJZD also significantly improved overall health status compared with placebo in per-protocol population (p = 0.009). No significant difference was found between groups in changes of SF36-PF, spleen deficiency scale scoring, and CGI. Fecal metagenome sequencing and correlation analyses indicated that the beneficial effect of SJZD may be related to the abundance change of Pediococcus acidilactici. No serious adverse event or abnormal laboratory test was found during the whole study. CONCLUSION: Our results indicated that SJZD can improve fatigue symptom and overall health status in patients with CFS under good medication adherence. Potential therapeutic effects may be related to the regulation of gut microbiota. Large-scale trials with longer intervention period are encouraged to further support SJZD's application. CLINICAL TRIAL REGISTRATION: (ID, ISRCTN23930966, URL = https://www.isrctn.com/ISRCTN23930966).

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Dai L, Liu Z, Zhou W, et al. Sijunzi decoction, a classical Chinese herbal formula, improves fatigue symptoms with changes in gut microbiota in chronic fatigue syndrome: A randomized, double-blind, placebo-controlled, multi-center clinical trial. Phytomedicine. 2024. PMID: 38640860. doi:10.1016/j.phymed.2024.155636

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。